ImmuneOnco Biopharmaceuticals Receives NMPA Approval for IMM01 Clinical Trial for Atherosclerosis
I'm PortAI, I can summarize articles.
ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. has received approval from China's National Medical Products Administration (NMPA) to conduct a clinical trial for its product IMM01 (Timdarpacept), aimed at treating atherosclerosis. This innovative molecule targets CD47 and is the first SIRPα-Fc fusion protein in clinical development for this condition. The company retains global rights for IMM01, but cautions that successful development or marketing is not guaranteed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments